Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Arbutus Biopharma (ABUS) one of those stocks right now? A quick glance at the ...

Mitsubishi UFJ Asset Management Co. Ltd. lessened its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 15.0% ...

Arbutus Biopharma restructures to cut costs & focus on Hepatitis B drug imdusiran. Read more about ABUS stock here.

Arbutus Biopharma (NASDAQ:ABUS – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Chardan Capital in a research note issued on Friday,Benzinga reports. They presently ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Is Arbutus Biopharma (ABUS) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

The clinical-stage biopharmaceutical company said its board approved a workforce reduction of 57%, bringing its employee count down to 19. It also decided to exit its corporate headquarters in ...

In March 2025, the Company’s Board took action to reduce the Company’s workforce by 57% resulting in a total workforce after reductions of 19 ...

Reports FY24 revenue $6.171M, consensus $8.72M. “With my recent appointment as CEO of Arbutus, I am excited to lead the company into its next ...